Provention Bio Inc.

01/27/2022 | Press release | Distributed by Public on 01/27/2022 15:15

Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA - Form 8-K